BRAF V600

缬氨酸600残基的BRAF突变已被证明在许多癌症类型中复发。在V600突变中，V600E是研究最广泛的。V600突变总体上与结直肠癌和乳头状甲状腺癌预后较差相关。V600突变也被证明对BRAF抑制剂达巴芬尼具有敏感性。要获得更详细的总结，请单击单个突变。
BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.